You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
佰仁醫療(688198.SH)2019年度淨利潤升88.88%至6308.49萬元 擬10派2元
格隆匯 04-21 19:33

格隆匯4月21日丨佰仁醫療(688198.SH)發佈2019年年度報告,實現營業收入1.46億元,同比增長31.98%;營業利潤7297.11萬元,同比增長76.17%;歸屬於母公司股東的淨利潤6308.49萬元,同比增長88.88%;歸屬於上市公司股東的扣除非經常性損益的淨利潤5887.63萬元,同比增長22.59%;基本每股收益0.88元,擬每10股派發現金紅利2元(含税)。

公司是國內技術領先的、專注於動物源性植介入醫療器械研發與生產的高新技術企業,產品主要包括人工生物心臟瓣膜-牛心包瓣、肺動脈帶瓣管道、瓣膜成形環、心胸外科生物補片、神經外科生物補片等12III類植介入醫療器械產品,主要應用於心臟瓣膜置換與修復、先天性心臟病植介入治療以及外科軟組織修復。

公司擁有原創性的動物組織工程和化學改性處理技術,可使處理後的動物組織植入人體後抗排異、抗鈣化、長期滿足預期治療要求。公司使用該技術生產的人工生物心臟瓣膜——牛心包瓣最早於2003年獲得註冊,是公司現有產品中最早獲得註冊的產品,也是國內最早註冊的人工生物心臟瓣膜國產產品。依據同源技術,公司進行了生物補片類產品的開發,應用於硬腦(脊)膜修復、疝修復以及心臟循環系統修復等。目前公司人工生物心臟瓣膜(牛心包瓣、豬主動脈瓣)、肺動脈帶瓣管道、瓣膜成形環、心胸外科生物補片、神經外科微血管減壓墊片6項產品均為國內首個獲准註冊的國產同類產品,填補了國內空白。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account